Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/IIa, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor

Next Previous
Trial Profile

Phase I/IIa, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGN-1 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pseudomyxoma peritonei; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Guangzhou Sinogen Pharmaceutical

Most Recent Events

  • 21 Feb 2024 Planned number of patients changed from 50 to 70.
  • 21 Feb 2024 Planned End Date changed from 31 Aug 2024 to 31 Aug 2028.
  • 21 Feb 2024 Planned primary completion date changed from 28 Feb 2024 to 18 Jan 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top